Research
-
Tesamorelin News Update: September 2026
A quiet quarter for the medicine itself: Egrifta's label and its narrow use did not change. The news came from around it, in FDA's letters to online sellers, WADA's 2027 list and three new papers.
-
Apitegromab Is Approved for SMA, Not Weight Loss
Apitegromab, sold as Isembyld, was approved on September 11, 2026, for spinal muscular atrophy only. A small trial with tirzepatide is why GLP-1 users heard about it. Here is what that trial did and did not show.
-
Wolverine Peptide Study: Use Is Up, Proof Isn't
A September preprint read de-identified doctors' notes and found new BPC-157 users up 33-fold since 2020, increasingly male and younger. It shows who is using it and where they get it, not whether it works.
-
Buy Semaglutide From Canada? What Sandoz Changes
Health Canada has now authorized generic semaglutide from four companies, Sandoz the latest on September 18. The U.S. rules on bringing it home haven't moved, and mailed parcels face new customs paperwork from October 22.
-
Counterfeit Retatrutide: The Vial Held Semaglutide
Australia's medicines regulator tested a vial sold as retatrutide after the person who used it was hospitalized. It held no retatrutide at all. Two days later, CBS News showed how a trust seal helped sellers look legitimate.
-
Enicepatide vs Tirzepatide: What the Results Mean
At its top dose, Roche's experimental weekly shot lowered A1c by 2.65 points and weight by 15.5% over 48 weeks in people with type 2 diabetes. It is approved nowhere, and its numbers can't yet be fairly set beside tirzepatide's.
-
FDA Green List GLP-1: What It Means for Your Vial
Twenty state attorneys general say FDA's list of cleared GLP-1 ingredient makers can be gamed, pointing to a Chinese supplier FDA caught relabeling semaglutide. What that case shows about where compounded semaglutide comes from, and what it doesn't change.
-
Glutathione Injection Recall: Why People Got Sick
More than 25 people fell ill after IV glutathione, and four Texas pharmacies have recalled vials. FDA traced the problem to one ingredient lot: glutathione powder labeled for supplements, not for a vein.
-
NAD IV Death: What the Medical Examiner Found
The NAD IV death of a 27-year-old woman at a Bronx wellness business has been ruled a homicide. The reported cause was air in her IV line: a failure in how the drip was given, rather than a reaction to the drug.
-
Novo Nordisk Name Change: What It Means
Novo Nordisk is becoming “Novo” in everyday use, with a new look and a new slogan. Its legal name remains the same, and the announcement does not change Wegovy, Ozempic, the Wegovy pill, or anyone’s prescription.
-
Petrelintide Starts Phase 3: A Plan, Not a Result
Zealand Pharma and Roche have begun three phase 3 trials of their once-weekly amylin shot in about 7,000 adults. The phase 2 numbers are encouraging and modest, and the answers that matter are more than a year away.
-
Sermorelin News Update: September 2026
This quarter was quiet: no new human trial changed the evidence, and July’s FDA compounding panel did not review sermorelin. The useful update is what has not changed—and which FDA list actually applies.
-
VK2735: Monthly Shots Held Most Weight Off, So Far
Viking says people kept most of their weight loss after moving from weekly VK2735 shots to monthly ones. What the 12-week study shows, what it can't tell you yet, and what it means for tirzepatide.
-
What Is Bioavailability? A Plain-English Guide
Bioavailability tells you how much of a medication reaches the place where the body can use it, and how quickly it gets there. The route and the exact formulation both matter.
-
CagriSema vs Tirzepatide: Ahead at 5 mg, Not 15 mg
Novo Nordisk's REIMAGINE 5 put its experimental combination ahead of tirzepatide 5 mg on weight loss in type 2 diabetes. Against full-dose tirzepatide, CagriSema has not come out ahead, and because it is not approved, for now it is available only in clinical trials.
-
Eloralintide Plus Tirzepatide: What the 17% Means
Lilly says adding its experimental amylin drug to a low dose of tirzepatide led to 17% weight loss in 16 weeks, against 10% on tirzepatide alone. Here is what that early number can and cannot tell you.
-
Generic Tirzepatide: Under Review, Not Approved
FDA has accepted applications for proposed generic tirzepatide autoinjectors, but none can be sold in the United States yet. Review, approval and launch are three different milestones.
-
Insurance Stopped Covering Wegovy? What Now
Massachusetts counted about 112,000 fewer commercially insured people using weight-loss GLP-1s in early 2026 after major insurers dropped coverage. Here is why plans are cutting, what that does not mean, and what is still open.
-
KPV FDA Review: What the July Vote Really Changed
KPV has never been approved as a U.S. drug. A July 2026 advisory vote favored possible 503A listing, but it did not change the list or approve a product.
-
WADA Prohibited List 2027: GLP-1s Off, BPC-157 On
WADA published its 2027 list on September 21. The weight-loss drugs stay on a watch list rather than the prohibited list, the peptides stay where they were, and a prescription is still not an exemption.
Page 6 of 8 · 160 articles